10-Q: Kewaunee Scientific Q3 Earnings Dip Amid Nu Aire Integration

Kewaunee Scientific reports a significant drop in Q3 net earnings despite overall sales growth, driven by increased tax expense and acquisition-related impacts.

Summary

• Net sales for the three months ended January 31, 2026, increased by 3.3% to $69.4 million, while nine-month sales rose 28.9% to $210.6 million, largely due to the Nu Aire acquisition.
• Net earnings attributable to Kewaunee Scientific Corporation decreased by 48.9% to $0.7 million ($0.23 diluted EPS) for the three-month period, and by 5.0% to $6.2 million ($2.09 diluted EPS) for the nine-month period.
• Gross profit margin for the quarter declined to 26.7% from 27.4% in the prior year, attributed to lower manufacturing volumes in laboratory construction and product mix changes.
• Operating expenses for the nine-month period increased by 34.1% to $47.7 million, primarily due to the Nu Aire acquisition and higher SG&A wages, benefits, incentive, and stock-based compensation.
• The company repaid $23.0 million in subordinated seller notes on December 4, 2025, partially funded by a new $10.0 million term loan and revolving credit facility draws.
• Order backlog decreased to $183.2 million at January 31, 2026, from $221.6 million a year prior.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative report. While top-line growth is evident, driven by the Nu Aire acquisition, the substantial decline in net earnings and EPS, coupled with a shrinking backlog, raises concerns about profitability and future revenue momentum.

Positives

• Overall net sales increased by 3.3% for the three months and 28.9% for the nine months ended January 31, 2026, demonstrating top-line growth.
• International sales showed strong growth, up 21.4% for the quarter and 27.0% for the nine months, primarily driven by increased billings in the Indian market.
• The Nu Aire acquisition has expanded the company's capabilities and product portfolio, offsetting softness in the traditional laboratory construction business.
• Operating profit increased by 14.8% for the three-month period and 24.2% for the nine-month period.
• Net cash provided by operating activities significantly increased to $13.2 million for the nine months, up from $5.4 million in the prior year.
• The company was in compliance with all financial covenants under its Amended Loan Agreement as of January 31, 2026.

Negatives

• Net earnings attributable to Kewaunee Scientific Corporation decreased significantly by 48.9% for the three-month period and 5.0% for the nine-month period.
• Diluted earnings per share decreased by 48.9% to $0.23 for the three-month period and by 5.0% to $2.09 for the nine-month period.
• Domestic sales for the quarter decreased by 2.0% compared to the prior year.
• Gross profit margin for the three months ended January 31, 2026, declined to 26.7% from 27.4% in the comparable prior year quarter.
• Order backlog decreased to $183.2 million at January 31, 2026, from $221.6 million at January 31, 2025, indicating potential future revenue pressure.
• Interest expense increased by 57.5% for the nine-month period to $3.2 million, due to changes in borrowing levels and interest rates.
• Cash and cash equivalents decreased from $14.9 million at April 30, 2025, to $8.2 million at January 31, 2026.

Risks

• Ability to realize the anticipated benefits from the Nu Aire acquisition.
• Competitive and general economic conditions, including disruptions from government mandates, supplier constraints, and other supply disruptions, both domestically and internationally.
• Changes in customer demands and dependence on customer-required delivery schedules.
• Technological changes in operations or the industry.
• Risks related to fluctuations in the company's operating results from quarter to quarter.
• Risks related to international operations, including foreign currency fluctuations.
• Changes in the legal and regulatory environment.
• Changes in raw materials and commodity costs, such as steel, wood, and epoxy resin.
• Acts of terrorism, war, governmental action, natural disasters, and other Force Majeure events.
• Volatility in project delivery timeliness and general slowdown of construction schedules in the winter months and prior to calendar year-end.

Future Outlook

The company anticipates continued volatility in project delivery timeliness, influenced by holiday schedules, winter construction slowdowns, and geopolitical/economic uncertainty. However, the strategic acquisition of Nu Aire is expected to offset softness in the traditional laboratory construction business, validating the company's growth and diversification strategy. Kewaunee Scientific remains committed to strategic investments in people, processes, and technology to support sustainable growth.

Management Comments

• Kewaunee's third quarter results for fiscal year 2026 align with the expectations previously communicated regarding volatility in project delivery timeliness and with historical trends.
• The softness of the construction-related portion of Kewaunee's business has been offset by the addition of Nu Aire's end-user containment products, validating the Company's ongoing growth and diversification strategy.
• The Company remains committed to its focus on growth and continuing strategic investments in the people, processes, and technology that will support and enable this growth in a sustainable manner.

Industry Context

StockSavvy.ai notes that Kewaunee Scientific's performance reflects broader industry trends where specialized laboratory and scientific equipment manufacturers are navigating a complex environment of fluctuating construction cycles and geopolitical uncertainties. The strategic acquisition of Nu Aire positions Kewaunee to diversify its revenue streams beyond traditional laboratory construction, moving into higher-growth segments like biological safety cabinets and ultralow freezers, which are critical for life sciences and healthcare sectors. This diversification strategy is crucial for resilience against cyclical downturns in large-scale construction projects and aligns with a growing demand for advanced laboratory containment and environmental control solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess results against global standards.
• Performance is primarily discussed in relation to prior periods and the impact of the Nu Aire acquisition, rather than direct comparisons to competitors or industry averages.

Corporate Governance

Stakeholder Impact

• Shareholders: Negative impact on net earnings and diluted EPS for the quarter and nine months. Decreased backlog could signal future revenue challenges. Share repurchase program remains authorized but no activity in the period.
• Employees: Increased SG&A wages, benefits, incentive, and stock-based compensation for the nine-month period.
• Customers: Nu Aire acquisition expands product offerings and capabilities, potentially better meeting diverse needs. Volatility in project delivery timeliness and construction slowdowns may affect project timelines.
• Creditors: Company is in compliance with all financial covenants under the Amended Loan Agreement. Significant debt repayment (Seller Notes) and new term loan indicate active debt management.
• Suppliers: Mention of supplier constraints and raw material cost fluctuations as risk factors.

Next Steps

• Continue evaluating other provisions of the OBBBA legislation for material impacts.
• Commence a new lease in the fourth quarter of fiscal year 2026.
• Record remaining estimated stock-based compensation expense of $2,797,000 over remaining vesting periods.
• Adopt ASU 2023-09 for annual reporting in fiscal year 2026.
• Adopt ASU 2024-03 for annual disclosures in fiscal year 2028 and interim disclosures in fiscal year 2029.

Key Dates

Recommendation

While Kewaunee Scientific demonstrates top-line growth driven by the strategic Nu Aire acquisition and strong international sales, the substantial decline in net earnings and diluted EPS for the quarter, along with a reduced order backlog, signals underlying profitability pressures and potential future revenue headwinds. The company's strategic diversification is positive, but the immediate financial results warrant a cautious approach. A 'hold' recommendation is appropriate as investors await clearer signs of successful integration, improved profitability margins, and stabilization of the backlog before considering further investment.

Keywords

Kewaunee Scientific, KEQU, SEC Filing, 10-Q, Quarterly Report, Financial Results, Laboratory Furniture, Scientific Equipment, Nu Aire Acquisition, Earnings, Sales, Backlog, Operating Profit, Diluted EPS, Cash Flow, Debt Repayment, Corporate Governance, Risk Factors, Biotech, Healthcare, Education, Life Sciences